![Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of](https://ascopubs.org/cms/10.1200/JCO.2017.76.9331/asset/images/large/jco.2017.76.9331t4.jpeg)
Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of
Bipacksedel: Information till patienten Everolimus Teva 2,5 mg Everolimus Teva 5 mg Everolimus Teva 7,5 mg Everolimus Teva 10 mg
![These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS. EVEROLIMUS tablets, for oral use Initial U.S. Approval: 2009 These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS. EVEROLIMUS tablets, for oral use Initial U.S. Approval: 2009](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=everolimus-tablets-a210050-3.jpg&id=739053)
These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS. EVEROLIMUS tablets, for oral use Initial U.S. Approval: 2009
![These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS. EVEROLIMUS tablets, for oral use Initial U.S. Approval: 2009 These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS. EVEROLIMUS tablets, for oral use Initial U.S. Approval: 2009](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=everolimus-tablets-a210050-9.jpg&id=739053)
These highlights do not include all the information needed to use EVEROLIMUS TABLETS safely and effectively. See full prescribing information for EVEROLIMUS TABLETS. EVEROLIMUS tablets, for oral use Initial U.S. Approval: 2009
![Comparing everolimus‐based immunosuppression with reduction or withdrawal of calcineurin inhibitor reduction from 6 months after heart transplantation: The randomized MANDELA study - Barten - 2019 - American Journal of Transplantation - Wiley Online ... Comparing everolimus‐based immunosuppression with reduction or withdrawal of calcineurin inhibitor reduction from 6 months after heart transplantation: The randomized MANDELA study - Barten - 2019 - American Journal of Transplantation - Wiley Online ...](https://onlinelibrary.wiley.com/cms/asset/0edea5a7-c839-43ed-b2c7-06636afdc1b9/ajt15361-fig-0002-m.jpg)
Comparing everolimus‐based immunosuppression with reduction or withdrawal of calcineurin inhibitor reduction from 6 months after heart transplantation: The randomized MANDELA study - Barten - 2019 - American Journal of Transplantation - Wiley Online ...
![An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients - ScienceDirect An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0085253819301930-fx1.jpg)